Objective: This study aimed to examine predictors and clinical outcomes of periprocedural myocardial infarction (PMI) after chronic total occlusion (CTO) intervention.
| I N TR ODU C TI ON
Periprocedural myocardial infarction (PMI) is a well-known complication of percutaneous coronary intervention (PCI) that is associated with worse outcomes [1, 2] . In particular, patients undergoing chronic total occlusion-PCI (CTO-PCI) may experience high rates of PMI owing to angiographic and procedural complexities. However, the incidence and clinical implications of PMI during CTO-PCI remain unclear, especially with the introduction of new-generation drug-eluting stents (DESs).
Compared with bare metal or first generation DESs, new-generation DESs have good long-term safety and efficacy due to their improved stent design, more favorable neointimal coverage, and diffusion mechanism [3] . Here, we investigated the incidence and predictors for PMI during CTO-PCI and evaluated the long-term clinical outcomes of patients in the new-generation DES era.
| M A TE RI A L S A ND M E TH ODS

| Study Population
Between 2012 and 2015, a total of 337 patients who underwent CTO-PCI and met the study criteria were consecutively enrolled from the YONSEI CTO registry, a single-center prospective registry.
The following patients were excluded: (1) patients who underwent PCI of concomitant non-CTO lesions or CTO-PCI using firstgeneration DESs, (2) clinical presentation as acute coronary syndrome, (3) history of any DES implantation shorter than 3 months, or (4) those without cardiac enzyme level measurements. The definition and duration of CTO and the general inclusion and exclusion criteria have been described in our previous studies [4, 5] . All CTO-PCI procedures included in this study were performed using the same protocol; all patients received aspirin (100 mg if previously administered or 200 mg as a loading dose if needed) and clopidogrel (75 mg if previously administered >5 days or a loading dose of 300 mg) before PCI. Dual antiplatelet therapy (DAPT) was prescribed for 12 months following PCI. Prasugrel and ticagrelor were not used in this study.
Before starting CTO-PCI, heparin 10,000 IU was administered, and we measured the activated clotting time (ACT) every 30 min during the procedure. ACT was maintained at >300 sec, and intracoronary heparin was administered if needed.
All patients underwent creatine kinase-MB (CK-MB) level measurements 6-8 and 18-24 hr after PCI. Clinical follow-up was performed 1, 6, and 12 months after PCI and annually thereafter through clinic visits or telephone contact. The institutional review board or ethics committee approved the study protocol, and all patients provided written informed consent before study entry.
| Endpoints and definitions
The primary endpoints of the study were to (i) identify predictors for PMI occurrence after CTO-PCI and (ii) determine the occurrence of major adverse cardiac and cerebrovascular events (MACCE), defined as the composite of cardiac death, myocardial infarction (MI), stent thrombosis, target-vessel revascularization, and cerebrovascular accidents. PMI was defined as CK-MB elevation 3 times the upper limit of normal (ULN, 5 ng/mL) after CTO-PCI [4, 5] . Clinical events were defined according to the Academic Research Consortium [6] . All deaths were considered to be of cardiac origin unless a definite noncardiac cause was established. MI was defined as a CK-MB elevation above the ULN or troponin T/I >99th percentile of the ULN, with concomitant ischemic symptoms or electrocardiographic findings indicative of ischemia unrelated to an interventional procedure [1, 6] . Stent thrombosis was defined as definite or probable stent thrombosis [6] . Side branch occlusion was defined as the absence or decrease of flow with thrombolysis in MI (TIMI) grade 1 of a side branch with diameter 2 mm on final angiogram [7] . Procedure and device success were defined as a final TIMI flow grade 2 without death or fatal complications requiring emergent operation during PCI or residual stenosis 30% on visual assessment after stent implantation, respectively [5] .
| Statistical analysis
Continuous variables are presented as mean 6 standard deviation and compared using Student's t-tests. Categorical variables are summarized as counts and percentages and compared using the chi-square test or
Fisher's exact test, as appropriate. A multivariate logistic analysis was performed to identify variables independently associated with PMI.
Any variable with P < 0.10 on univariate analysis or displaying significant relationships with PMI occurrence after CTO-PCI in previous studies (side branch occlusion, retrograde wiring approach, or procedure failure) was included in the multivariate models [2, 8, 9] . Cumulative event rates were calculated using the Kaplan-Meier method and compared with log-rank tests. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard regression. Variables that were significantly related with MACCE after CTO-PCI in previous studies (procedure success, age, sex, diabetes mellitus, multivessel disease) were included in the Cox regression models [8, 10, 11] . All statistical analyses were conducted with SPSS statistical software (version 21.0; IBM Corp., Armonk, NY, USA). A two-sided Pvalue of <0.05 was considered statistically significant.
| RE S U L TS
| Baseline characteristics
Among the 337 patients enrolled in this study, PMI occurred in 23 (6.8%). Compared with the non-PMI group, patients with PMI had a higher incidence of previous coronary artery bypass grafting (CABG) and lower left ventricular ejection fraction (Table 1) . Regarding angiographic and procedure characteristics, patients in the PMI group were more likely to have a blunt stump, side branch occlusion, high J-CTO score, and longer procedure time than the non-PMI group (Table 1) .
| Predictors for PMI
On multiple logistic regression after adjustment, previous CABG, J-CTO score 3, side branch occlusion, and longer procedure time (>90th percentile) remained statistically significant independent risk factors for PMI (Table 2 ). When we compared the characteristics according to the presence of previous CABG, the patients with previous CABG were more likely to have a frequent previous MI, a lower ejection fraction, a prolonged procedure time, and a relatively high J-CTO score (Supporting Information Table S1 ). Figure 1A ). In addition, the PMI group showed significantly higher incidences of MACE and the composite of cardiac death, MI, and stent thrombosis than the non-PMI group ( Figure 1B,C) . In analyses for patients with procedure success (n 5 275), the PMI group consistently had a significantly higher MACCE rate than the non-PMI Table 2 , the group with multiple risk factors (number of risk factors 3) had a significantly higher MACCE rate than the other groups (groups with 0, 1, or 2 risk factors, P < 0.001, Figure 2 ).
| Clinical outcomes according to CK-MB Level
Regardless of the various definitions of PMI (any increase or an elevation 53 or 103 ULN), patients with PMI had a significantly increased risk of MACCE ( Figure 3A -C). When we compared MACCE rates according to peak CK-MB level after CTO-PCI, it gradually increased, with the highest risk in patients with 103 ULN (log-rank P 5 0.005; Figure 3D ).
| D ISC USSION
The major findings of our study using data from the new-generation era are as follows: (i) the incidence of PMI was 6.8%; (ii) independent predictors of PMI were a history of bypass surgery, high J-CTO score The prevalence of PMI in this CTO study was 6.8%, similar to previously reported rates of 8.6-18.3% [2, 8, 12] . Although CTO-PCI might confer a higher risk of PMI owing to lesion and procedure complexities, the prevalence of PMI in the current study was quite similar to that reported in non-CTO PCI studies [13] [14] [15] [16] [17] . This may be due to the use of advanced techniques and novel devices in the new-generation DES era that further improved CTO success rates [18, 19] .
Several factors could influence the occurrence of PMI after CTO-PCI. Patients with previous bypass surgery as a clinical factor are highly likely to have a multivessel disease, relatively long CTO duration, and severe calcification, which could be strongly related to a high risk of PMI occurrence after PCI [20] . Patients with a history of bypass surgery were more likely to have a prolonged procedure time and high J-CTO score (Supporting Information Table S1 ). A J-CTO score 3, a well-known preprocedural risk score for successful wire passage, was significantly associated with PMI. Recent publications reported that the J-CTO score could be related to clinical outcomes after successful CTO-PCI, in addition to its role predicting procedure success or failure Values are presented as numbers and the cumulative event rates (%), calculated by using the Kaplan-Meier method. a P-Values were from the log-rank test.
Abbreviations: CI, confidence interval; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; PMI, periprocedural myocardial infarction.
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| 5 [18, [21] [22] [23] . Concerning side branch occlusion after CTO-PCI, a previous study showed that the most common mechanism of PMI was side branch occlusion, even in the small side branch (2 mm) [24, 25] .
Finally, a longer procedure time was a significant predictor for PMI in our patients undergoing CTO-PCI. Other studies reported significantly longer total procedure or fluoroscopy time in patients with PMI during CTO-PCI than in those without PMI [2, 9] . A longer total procedure time could confer a higher risk of thrombus formation or a greater chance of injury to the coronary artery and microvascular system, and might reflect a need for more predilatation or postdilatation and the use of complex techniques for CTO crossing [26, 27] .
Although PMI after PCI was previously associated with worse clinical outcomes, the relationship between PMI during CTO-PCI and its clinical outcomes remained controversial. Di Serafino et al. reported that PMI, defined as elevated troponin, was not associated with clinical outcomes [9] . Jang et al. concluded that PMI after revascularization, including CABG, did not increase cardiac death or adverse cardiac events [12] . Recent CTO studies demonstrated that PMI after CTO-PCI could be related to worse subsequent clinical outcomes [2, 8, 28] .
Our study yielded similar results. Notably, we only included patients successfully treated with new-generation DESs, which have shown superior long-term clinical outcomes over first-generation DESs, and The total MACE rate (4.2%) in our study was relatively low, compared to that of the TWENTE trial (15.3%) that treated by CTO-PCI using the newer-generation DES [29] . However, 42.4% of the patients in TWENTE trial were treated for multivessel lesion (2), but those in our study were treated for single-vessel involving CTO lesion. Also, antegrade wire approach was only performed in CTO-PCI of TWENTE trial, but we performed retrograde wire approach as well as antegrade wire approach. These differences in study popula- 
| Study limitations
Our results must be interpreted in the context of some limitations.
Although this was a retrospective, single-center study, only designated interventionists following a similar CTO-PCI strategy and patient management plan performed CTO-PCI, and these could be advantageous in evaluating the effect of PMI itself on long-term clinical outcomes. Second, because we only included the patients fulfilling the specific study criteria (exclusion of patients with concomitant non-CTO lesions, acute coronary syndrome presentation, or recent other vessel stenting), the study population was small, and the observational period was limited.
However, these features also increase the focus on the pure effects of PMI following CTO-PCI. Finally, we checked only CK-MB levels to evaluate for PMI. Due to Korean insurance coverage restrictions, troponin levels after CTO-PCI were not measured.
| CON CL U S I ON
In conclusion, independent predictors of PMI after CTO-PCI were a history of bypass surgery, high J-CTO score, side branch occlusion, and longer procedure time. PMI occurrence and peak CK-MB level after CTO-PCI were significantly associated with worse clinical outcomes in the new-generation DES era.
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